401A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the Beta-lactamase inhibitor RPX7009 Alone, Meropenem Alone, and both in Combination (Carbavance) TID for 7 days in Healthy Adult Subjects. (December 2014) - Griffith, David; Rubino, Christopher; Loutit, Jeff; Morgan, Elizabeth; White, Dan; Dudley, Michael